Life Sciences

  • May 07, 2026

    Bayer Sued Over Healthy Sperm Claim On 'One A Day' Pill

    Bayer AG has been hit with a proposed class action in New York federal court alleging that claims on its Men's One A Day Pre-Conception Health Multivitamin supplements misleadingly convey that they could improve chances of conception and support sperm health.

  • May 07, 2026

    Bayer Loses Bid To Undo Class In 'One A Day' Label Suit

    A New York federal judge on Wednesday declined to decertify a class action alleging that Bayer's "One A Day" gummy vitamins deceive consumers about serving sizes, allowing the case to continue since there's evidence that a significant number of consumers could be confused.

  • May 07, 2026

    Liberty Left Client Info Vulnerable To Hackers, Suit Alleges

    Liberty Mutual Insurance Co. faces a proposed consumer class action alleging it failed to effectively safeguard private information for current and former clients after hackers claimed they stole information and sought a ransom payment.

  • May 07, 2026

    Judge Knocks Out Pfizer Partner's Vax Case Against GSK

    A Delaware federal judge on Thursday threw out a suit seeking a finding that a drug developer that partnered with Pfizer and BioNTech on their COVID-19 vaccine didn't infringe drugmaker GlaxoSmithKline's patents.

  • May 07, 2026

    Pharma Cos. Hit With $2M Judgment Over CBD Investor Fraud

    A California federal judge has issued final judgments against a pharmaceutical company, its CEO and an affiliate on claims from the U.S. Securities and Exchange Commission that they defrauded investors of $6.6 million, hitting them with more than $2 million in damages and civil penalties.

  • May 07, 2026

    AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit

    Female pharmaceutical sales representatives in an AstraZeneca equal pay suit have urged an Illinois federal court to reject the company's bid to dismiss two dozen opt-in plaintiffs for refusing discovery, saying the women feared retaliation and career consequences.

  • May 07, 2026

    Ex‑Novartis Atty Wins Revival Of Whistleblower Claims

    The New Jersey state appeals court on Thursday revived five whistleblower claims brought by a former Novartis compliance attorney, finding that a trial judge wrongly treated a years‑long pattern of alleged retaliation as discrete, time‑barred events rather than a continuous campaign culminating in her 2021 termination.

  • May 07, 2026

    Davis Polk-Led Roche To Pay Up To $1.05B For PathAI

    Davis Polk & Wardwell LLP is advising Roche on a deal announced Thursday that would see the Swiss healthcare company purchase a Boston-based, AI-powered digital pathology company for up to $1.05 billion.

  • May 07, 2026

    King & Spalding Adds Congressional Health Policy Duo In DC

    Two former congressional staffers experienced in health policy recently joined King & Spalding LLP in its Washington, D.C., office, the firm announced this week.

  • May 07, 2026

    Gilead Accuses Pharmacies Of Selling Counterfeit HIV Drugs

    Gilead Sciences has sued several New York City pharmacies claiming they sold counterfeit HIV medication bearing the Gilead brand.

  • May 07, 2026

    Toss Of Ex-Shkreli Atty's Deal May Be Error, 2nd Circ. Hints

    A Second Circuit judge hinted Thursday that a trial judge may have erred in rejecting a retirement-fund garnishment deal that would have protected Martin Shkreli's convicted former lawyer from a potential $1 million "punitive tax event."

  • May 07, 2026

    FBI Assistant GC Joins FBI Alum At Fenwick

    Fenwick & West LLP has hired the former assistant general counsel of the FBI, who will work as a counsel to support technology and life sciences companies and who is rejoining the former FBI director's chief of staff in the Washington, D.C., office.

  • May 06, 2026

    Corcept Must Face Most Teva Mifepristone Antitrust Claims

    A California federal judge on Tuesday once again mostly refused to throw out Teva Pharmaceuticals' claims that Corcept Therapeutics used patent system abuse, bribes and exclusive dealing to block generic competition to its cortisol disorder treatment, finding that at this stage in the litigation the allegations are adequate.

  • May 06, 2026

    J&J, Tolmar Settle Patent Case Over Antipsychotic Drug

    A federal court Wednesday signed off on a consent judgment in a patent case brought by a Johnson & Johnson unit that prevents Tolmar Inc. from selling a generic version of the blockbuster schizophrenia drug Invega Sustenna.

  • May 06, 2026

    'Do Not Use This Report': J&J Hid Asbestos Test, Jury Told

    Johnson & Johnson and a consultant it hired in the 1970s altered the conclusions of tests that found alarming levels of asbestos in the company's talc products before giving different results to the U.S. Food and Drug Administration, a former FDA commissioner told a Los Angeles jury Wednesday.

  • May 06, 2026

    Trulieve Twists Patent Pleading Standard, Cannabis Co. Says

    A cannabis patent holder urged a Florida federal court to reject Trulieve Inc.'s effort to toss an infringement complaint, arguing that proof of its claims isn't needed when initially filing a lawsuit. 

  • May 06, 2026

    Judge Questions OMB Justification For Voiding Grants

    A Massachusetts federal judge on Wednesday pushed back on arguments by the Trump administration that federal agency grants are subject to termination at any time based solely on a change in priorities — a situation, she suggested, that would essentially render any contracts with the government "illusory."

  • May 06, 2026

    Judge Won't Certify Minn. Fraud Question In Cancer Drug MDL

    A New Jersey federal judge won't ask the Supreme Court of Minnesota to weigh in on whether an insurer can pursue claims using a state law typically reserved for the attorney general in litigation alleging drugmaker Celgene used charitable donations to manipulate the price of cancer drugs.

  • May 06, 2026

    Calif. Justices Seem Divided On Gilead HIV Negligence Claim

    The California Supreme Court appeared split Wednesday over whether Gilead should face a negligence claim for allegedly withholding a safer HIV drug from the market to maximize profits from an older drug with more harmful side effects. 

  • May 06, 2026

    9th Circ. Won't Revive Hospital Workers' Vaccine Bias Suit

    The Ninth Circuit refused Wednesday to reopen a religious bias lawsuit accusing a Washington hospital of unlawfully denying employees' requests to avoid a COVID-19 vaccination mandate, finding that the medical center demonstrated that exemptions would've been too burdensome under a 2023 U.S. Supreme Court decision.

  • May 06, 2026

    Alto Says Investors Use Hindsight In Suit Over Drug Trial

    Alto Neuroscience has urged a California federal judge to toss an investor suit alleging the psychiatric biotech company and its top brass overstated the efficacy of their lead drug candidate for treating major depressive disorder, saying the suit is a "classic case of trying to plead fraud by hindsight."

  • May 06, 2026

    CellCentric Closes Latest Funding Round With $220M In Tow

    Clinical-stage biotechnology company CellCentric on Wednesday revealed that it closed its oversubscribed Series D financing round after securing $220 million from investors.

  • May 05, 2026

    DC Circ. Judge Jabs Pharma Atty For 10 Minutes In Price Fight

    The first D.C. Circuit showdown in widespread drug pricing litigation Tuesday appeared unlikely to deliver a badly needed win to the pharmaceutical industry, as a top manufacturer's attorney faced a cool reception generally and an extended barrage of skepticism from one judge.

  • May 05, 2026

    Ex-FDA Chief Testifies 100s Of J&J Docs Tie Asbestos To Talc

    A former U.S. Food and Drug Administration commissioner on Tuesday testified in a Los Angeles bellwether trial over claims Johnson & Johnson's talc products caused deadly ovarian cancer in three women, saying hundreds of internal company documents reveal the company knew for decades that its talc contained asbestos.

  • May 05, 2026

    Cannabis Giants Sued Over Mental Health Marketing

    Recreational cannabis users hit some of the industry's largest companies — Cresco Labs, Green Thumb Industries, Verano Holdings and Curaleaf — with two sprawling lawsuits alleging the businesses overcharged for products deceptively marketed as safe and effective treatments for mental health disorders.

Expert Analysis

  • Series

    Volunteering With Scouts Makes Me A Better Lawyer

    Author Photo

    Serving as an assistant scoutmaster for my son’s troop reaffirmed several skills and principles crucial to lawyering — from the importance of disconnecting to the value of morality, says Michael Warren at McManis Faulkner.

  • Series

    Law School's Missed Lessons: In Court, It's About Storytelling

    Author Photo

    Law school provides doctrine, cases and hypotheticals, but when lawyers step into the courtroom, they must learn the importance of clarity, credibility, memorability and preparation — in other words, how to tell simple, effective stories, say Nicholas Steverson and Danielle Trujillo at Wheeler Trigg, and Lisa DeCaro at Courtroom Performance.

  • Pros And Cons Of FDA's Push For Nonprescription Drugs

    Author Photo

    The U.S. Food and Drug Administration's recent moves to shift more prescription drugs to over-the-counter status could increase access to important medications, but also bring potential safety risks and other trade-offs for drug companies, say attorneys at Hogan Lovells.

  • How Recent Del. Rulings Clarify M&A Deal Fraud Carveouts

    Author Photo

    Two recent Delaware decisions have provided clarity regarding when a party can or cannot rely on representations made during the course of an M&A transaction, particularly on the scope and enforceability of antireliance provisions, and on representations they knew or should have known were false, says Anthony Boccamazzo at Olshan Frome.

  • High Court's 'Skinny Label' Case May Tackle Wider Questions

    Author Photo

    The U.S. Supreme Court's upcoming decision in Hikma v. Amarin will have important ramifications for broader debates over what defines a generic version of a drug, and the pending case is already altering patent practice, say attorneys at Taft.

  • Aligning Microsoft Tools With NYC Bar AI Recording Guidance

    Author Photo

    The New York City Bar Association’s recently issued formal opinion, providing ethical guidance on artificial intelligence-assisted recording, transcription and summarization, raises immediate questions about data governance and e-discovery for companies that use Microsoft 365 and Copilot, say Staci Kaliner, Martin Tully and John Collins at Redgrave.

  • FDA's Biosimilarity Guidance Holds Uncertain Implications

    Author Photo

    The U.S. Food and Drug Administration's new draft guidance aimed at simplifying the biosimilarity demonstration process may not be enough to overcome the barriers that have historically constrained biosimilar competition, and could affect biosimilar access in unexpected ways, say analysts at Analysis Group.

  • Unpacking Key Themes From NY's New Healthcare Strategy

    Author Photo

    New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.

  • 5 Different AI Systems Raise Distinct Privilege Issues

    Author Photo

    A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.